.Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AA07_Rosuvastatin.Rosuvastatin .Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AA07_Rosuvastatin.Rosuvastatin| name: | Rosuvastatin |
| ATC code: | C10AA07 | route: | oral |
| n-compartments | 2 |
Rosuvastatin is a synthetic lipid-lowering agent, classified as a statin (HMG-CoA reductase inhibitor), used for the treatment of high cholesterol and related conditions, and for the prevention of cardiovascular disease. It is widely approved and prescribed globally.
Population pharmacokinetics in healthy adult volunteers (both sexes), single oral dose.
Shah, Y, et al., & Ullah, Z (2019). Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. Pakistan journal of pharmaceutical sciences 32(6) 2725–2732. PUBMED:https://pubmed.ncbi.nlm.nih.gov/31969307
Tzeng, TB, et al., & Kung, LP (2008). Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Current medical research and opinion 24(9) 2575–2585. DOI:10.1185/03007990802312807 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18674408
Liao, M, et al., & Xiao, JJ (2022). Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clinical pharmacokinetics 61(11) 1477–1493. DOI:10.1007/s40262-022-01157-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36107395